-
1.发明授权Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 有权治疗与淀粉样β1-42的可溶性低聚物种相关的疾病的方法公开(公告)号：US09320793B2
公开(公告)日：2016-04-26
申请号：US13693362
申请日：2012-12-04
发明人： William F. Goure , Franz F. Hefti , Renee C. Gaspar , Paul J. Shughrue , Fubao Wang , Weirong Wang , Ningyan Zhang , Wei-Qin Zhao , Alexander McCampbell , Min Xu
IPC分类号： A61K39/395 , C07K16/18 , A61K45/06 , A61K39/00
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation.
摘要翻译： 本发明是一种用于治疗与可溶性低聚物淀粉样蛋白β1-42的积累相关或由其引起的疾病的方法和试剂盒，其使用对淀粉样蛋白β1-42寡聚体具有较高亲和力的抗体或其抗体片段， 淀粉样蛋白β1-42单体，淀粉样蛋白β1-40单体，斑块和淀粉样蛋白β原纤维，以及任选的tau治疗剂或淀粉样β生成或聚集抑制剂。
-
2.发明申请NOVEL ADDL RECEPTOR POLYPEPTIDES, POLYNUCLEOTIDES AND HOST CELLS FOR RECOMBINANT PRODUCTION 有权新型ADDL受体多肽，多核苷酸和重组体生产的宿主细胞公开(公告)号：US20100303897A1
公开(公告)日：2010-12-02
申请号：US12745887
申请日：2008-12-17
申请人： Jasna Jerecic
发明人： Jasna Jerecic
IPC分类号： A61K39/395 , C07K14/705 , A61K38/17 , C07H21/00 , A61K31/7088 , C12P21/02 , C12N5/00 , C07K16/28 , C12N5/12 , G01N33/567 , A61P25/28 , A61P25/00 , A61K9/127 , A61K9/14
CPC分类号： C07K14/705
摘要： This invention provides a novel receptor expressed on neuronal cells in a developmentally-specific manner. Accordingly, this invention provides the amino acid sequences of selected portions of the receptor and polynucleotides encoding these portions as well as antibodies that bind to the polypeptide portions of the receptor. Compositions and methods for using the compositions are also provided.
摘要翻译： 本发明提供了以发育特异性方式在神经细胞上表达的新型受体。 因此，本发明提供受体的选定部分的氨基酸序列和编码这些部分的多核苷酸以及结合受体多肽部分的抗体。 还提供了组合物和使用该组合物的方法。
-
3.发明申请METHODS OF MODIFYING AMYLOID beta OLIGOMERS USING NON-PEPTIDIC COMPOUNDS 有权使用非特异性化合物改性AMYLOIDβ低聚物的方法公开(公告)号：US20090018218A1
公开(公告)日：2009-01-15
申请号：US11777264
申请日：2007-07-12
申请人： Grant A. Krafft , Todd Pray , William F. Goure
发明人： Grant A. Krafft , Todd Pray , William F. Goure
CPC分类号： A61K9/2054 , A61K9/0019 , A61K9/0075 , A61K9/02 , A61K9/146 , A61K9/2059 , A61K31/381 , A61K31/41 , A61K31/415 , C12N5/0619 , C12N2501/999
摘要： Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers from amyloid β1-42 monomers. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers.
摘要翻译： 公开了抑制，调节和/或调节淀粉样蛋白β1-42单体形成可溶性，球状，非纤维状，神经毒性淀粉样蛋白β1-42寡聚体的方法。 还公开了治疗患有与可溶性，球状，非纤维状，神经毒性淀粉样β1-42寡聚体形成相关的疾病的患者的方法。
-
4.发明授权ADDL receptor polypeptides, polynucleotides and host cells for recombinant production 有权ADDL受体多肽，多核苷酸和用于重组生产的宿主细胞公开(公告)号：US09217024B2
公开(公告)日：2015-12-22
申请号：US12745887
申请日：2008-12-17
申请人： Jasna Jerecic , Grant A. Krafft
发明人： Jasna Jerecic , Grant A. Krafft
IPC分类号： A61P25/28 , A61P25/00 , A61K39/395 , C07K14/705
CPC分类号： C07K14/705
摘要： This invention provides a novel receptor expressed on neuronal cells in a developmentally-specific manner. Accordingly, this invention provides the amino acid sequences of selected portions of the receptor and polynucleotides encoding these portions as well as antibodies that bind to the polypeptide portions of the receptor. Compositions and methods for using the compositions are also provided.
摘要翻译： 本发明提供了以发育特异性方式在神经细胞上表达的新型受体。 因此，本发明提供受体的选定部分的氨基酸序列和编码这些部分的多核苷酸以及结合受体多肽部分的抗体。 还提供了组合物和使用该组合物的方法。
-
公开(公告)号：US09176151B2
公开(公告)日：2015-11-03
申请号：US13544600
申请日：2012-07-09
申请人： William F. Goure , Renee C. Gaspar , Alexander McCampbell , Mary J. Savage , Paul J. Shughrue , Fubao Wang , Weirong Wang , Abigail L. Wolfe , Nigyan Zhang , Wei-Qin Zhao
发明人： William F. Goure , Renee C. Gaspar , Alexander McCampbell , Mary J. Savage , Paul J. Shughrue , Fubao Wang , Weirong Wang , Abigail L. Wolfe , Nigyan Zhang , Wei-Qin Zhao
IPC分类号： C07K16/18 , G01N33/532 , G01N33/68
CPC分类号： G01N33/6896 , C07K16/18 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N2333/4709 , G01N2800/2821
摘要： This invention is a selective Aβ oligomer kit and immunoassay method capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, as capture and detection antibodies, to detect and quantify Aβ oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.
摘要翻译： 本发明是一种选择性的 低聚物试剂盒和免疫测定法，能够可靠而灵敏地检测A＆bgr; 患者生物样品中的低聚物。 在一个实施方案中，本发明的测定使用一对抗A＆bgr; 低聚物抗体作为捕获和检测抗体，用于检测和定量A＆bgr; 低聚物。 该方法可用于区分阿尔茨海默病（AD）患者和非AD患者和/或根据其疾病的严重程度分层AD患者。
-
6.发明授权公开(公告)号：US09006283B2
公开(公告)日：2015-04-14
申请号：US11777264
申请日：2007-07-12
申请人： Grant A. Krafft , Todd Pray , William F. Goure
发明人： Grant A. Krafft , Todd Pray , William F. Goure
IPC分类号： A61K31/381 , A61K31/4155 , A61K9/20 , A61K9/00 , A61K9/02 , A61K9/14 , A61K31/41 , A61K31/415 , C12N5/0793
CPC分类号： A61K9/2054 , A61K9/0019 , A61K9/0075 , A61K9/02 , A61K9/146 , A61K9/2059 , A61K31/381 , A61K31/41 , A61K31/415 , C12N5/0619 , C12N2501/999
摘要： Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers from amyloid β1-42 monomers. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers.
摘要翻译： 公开了抑制，调节和/或调节来自淀粉样蛋白和1-42单体的可溶性，球状，非纤维状，神经毒性淀粉样蛋白和β-葡聚糖1-42寡聚体的形成的方法。 还公开了治疗患有与可溶性，球状，非纤维状，神经毒性淀粉样蛋白和β-葡聚糖1-42寡聚体形成相关的疾病的患者的方法。
-
公开(公告)号：US20130130288A1
公开(公告)日：2013-05-23
申请号：US13544600
申请日：2012-07-09
申请人： William F. Goure
发明人： William F. Goure , Renee C. Gaspar , Alexander McCampbell , Mary J. Savage , Paul J. Shughrue , Fubao Wang , Weirong Wang , Abigail L. Wolfe , Nigyan Zhang , Wei-Qin Zhao
IPC分类号： G01N33/68
CPC分类号： G01N33/6896 , C07K16/18 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N2333/4709 , G01N2800/2821
摘要： This invention is a selective Aβ oligomer kit and immunoassay method capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, as capture and detection antibodies, to detect and quantify Aβ oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.
摘要翻译： 本发明是一种能够可靠和敏感地检测患者生物样品中的Aβ寡聚体的选择性Abeta寡聚体试剂盒和免疫测定方法。 在一个实施方案中，本发明的测定使用一对抗Abeta寡聚体抗体作为捕获和检测抗体来检测和定量Aβ寡聚体。 该方法可用于区分阿尔茨海默病（AD）患者和非AD患者和/或根据其疾病的严重程度分层AD患者。
-
8.发明申请METHOD FOR TREATING A DISEASE ASSOCIATED WITH SOLUBLE, OLIGOMERIC SPECIES OF AMYLOID BETA 1-42 有权用于治疗与可溶性疾病相关的疾病的方法，低分子量的AMYLOID BETA 1-42公开(公告)号：US20130089537A1
公开(公告)日：2013-04-11
申请号：US13693362
申请日：2012-12-04
发明人： William F. Goure , Franz F. Hefti , Renee C. Gaspar , Paul J. Shughrue , Fubao Wang , Weirong Wang , Ningyan Zhang , Wei-Qin Zhao
IPC分类号： A61K39/395 , A61K45/06 , C07K16/18
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation.
摘要翻译： 本发明是一种用于治疗与可溶性低聚物淀粉样蛋白β1-42的积累相关或由其引起的疾病的方法和试剂盒，其使用对淀粉样蛋白β1-42寡聚体具有较高亲和力的抗体或其抗体片段， 淀粉样蛋白β1-42单体，淀粉样蛋白β1-40单体，斑块和淀粉样蛋白β原纤维，以及任选的tau治疗剂或淀粉样β生成或聚集抑制剂。
-
公开(公告)号：US20090018084A1
公开(公告)日：2009-01-15
申请号：US11777266
申请日：2007-07-12
申请人： Grant A. KRAFFT , Todd Pray , William F. Goure
发明人： Grant A. KRAFFT , Todd Pray , William F. Goure
CPC分类号： A61K31/00 , A61K31/34 , A61K31/381 , A61K31/415
摘要： Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from Aβ1-42 monomers.
摘要翻译： 公开了增强认知障碍的方法，其中认知障碍是由于ADDL神经毒性引起的。 该方法采用分子量小于1000的非肽类化合物，可以拮抗Abeta1-42单体形成神经毒性ADDL。
-
公开(公告)号：US09310383B2
公开(公告)日：2016-04-12
申请号：US14729343
申请日：2015-06-03
发明人： William F. Goure , Renee C. Gaspar , Alexander McCampbell , Mary J. Savage , Paul J. Shughrue , Fubao Wang , Weirong Wang , Abigail L. Wolfe , Ningyan Zhang , Wei-Qin Zhao , Min Xu
IPC分类号： C07K16/18 , G01N33/577 , G01N33/68
CPC分类号： G01N33/6896 , C07K16/18 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N2333/4709 , G01N2800/2821
摘要： This invention is a selective Aβ oligomer kit and immunoassay method capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, as capture and detection antibodies, to detect and quantify Aβ oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.032 秒)